

Supplementary file

Methods

The following “Summary of Product Characteristics” and publications were used for the identification of phase III clinical trials for the respective drug: ocrelizumab¹; cladribine²; daclizumab³; dimethyl fumarate⁴; teriflunomide⁵; alemtuzumab⁶; fingolimod⁷; natalizumab⁸; mitoxantrone^{9,10}; glatiramer acetate¹¹; peginterferon β -1a¹²; interferon β -1a^{13,14}; interferon β -1b¹⁵.

References

1. European Medicines Agency - Committee for Medicinal Products for Human. Ocrevus EPAR - Product Information: Ocrevus - EMEA/H/C/004043, https://www.ema.europa.eu/en/documents/assessment-report/ocrevus-epar-public-assessment-report_en.pdf (2020, accessed 19 May 2020).
2. European Medicines Agency - Committee for Medicinal Products for Human. Mavenclad EPAR - Product Information: Mavenclad - EMEA/H/C/004230 - IB/0012, https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_en.pdf (2020, accessed 12: 05: 2020, 19:46).
3. European Medicines Agency - Committee for Medicinal Products for Human. Zinbryta EPAR - Product Information: EMEA/H/C/003862 - IB/0015, https://www.ema.europa.eu/en/documents/product-information/zinbryta-epar-product-information_en.pdf (2016, accessed 14 October 2019).
4. European Medicines Agency - Committee for Medicinal Products for Human. Tecfidera EPAR - Product Information: EMEA/H/C/002601 - II/0058,

https://www.ema.europa.eu/en/documents/product-information/tecfidera-epar-product-information_en.pdf (2020, accessed 19 May 2020).

5. European Medicines Agency - Committee for Medicinal Products for Human. Aubagio EPAR - Product Information: Aubagio - EMEA/H/C/002514, https://www.ema.europa.eu/en/documents/product-information/aubagio-epar-product-information_en.pdf (2020, accessed 19 May 2020).
6. European Medicines Agency - Committee for Medicinal Products for Human. Lemtrada EPAR - Product Information: EMEA/H/C/003718 - A20/0028, https://www.ema.europa.eu/en/documents/product-information/lemtrada-epar-product-information_en.pdf (2020, accessed 19 May 2020).
7. European Medicines Agency - Committee for Medicinal Products for Human. Gilenya EPAR - Product Information: EMEA/H/C/002202 - PSUSA/00001393/201902, https://www.ema.europa.eu/en/documents/product-information/gilenya-epar-product-information_en.pdf (2019, accessed 9 October 2019).
8. European Medicines Agency - Committee for Medicinal Products for Human. Tysabri EPAR - Product Information: EMEA/H/C/000603 - PSUSA/00002127/201908, https://www.ema.europa.eu/en/documents/product-information/tysabri-epar-product-information_en.pdf (2020, accessed 19 May 2020).
9. European Medicines Agency - Committee for Medicinal Products for Human. Novantrone and associated names Article-30 referral - Assessment report, https://www.ema.europa.eu/en/documents/referral/novantrone-associated-names-article-30-referral-assessment-report_en.pdf (2016, accessed 10 October 2019).

10. Kieseier BC, Gold R and Hartung H-P. Mitoxantron zur Therapie der Multiplen Sklerose. *Nervenarzt* 2003; 74: 906–910.
11. Weinstock-Guttman B, Nair KV, Glajch JL, et al. Two decades of glatiramer acetate: From initial discovery to the current development of generics. *J Neurol Sci* 2017; 376: 255–259.
12. European Medicines Agency - Committee for Medicinal Products for Human. Plegridy EPAR - Product Information: EMEA/H/C/002827 - II/0052/G, https://www.ema.europa.eu/en/documents/product-information/plegridy-epar-product-information_en.pdf (2019, accessed 20 May 2020).
13. European Medicines Agency - Committee for Medicinal Products for Human. Rebif EPAR - Product Information: EMEA/H/C/000136 - II/0144, https://www.ema.europa.eu/en/documents/product-information/rebif-epar-product-information_en.pdf (2020, accessed 20 May 2020).
14. European Medicines Agency - Committee for Medicinal Products for Human. Avonex EPAR - Product Information: EMEA/H/C/000102 - II/0182/G, https://www.ema.europa.eu/en/documents/product-information/avonex-epar-product-information_en.pdf (2019, accessed 20 May 2020).
15. European Medicines Agency - Committee for Medicinal Products for Human. Betaferon EPAR - Product Information: EMEA/H/C/000081 - II/0124/G, https://www.ema.europa.eu/en/documents/product-information/betaferon-epar-product-information_en.pdf (2019, accessed 20 May 2020).